CD200 and CD200R1 are differentially expressed and have differential prognostic roles in non-small cell lung cancer

References

• Teng MWL, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers basedon T-cell infiltration and PD-L1. Cancer Res. 2015;2139–15. doi:10.1158/0008-5472.CAN-15-0255.
   PubMed Web of Science ®Google Scholar
• Yoshimura K, Inoue Y, Kahyo T, Kawase A, Tanahashi M, Ogawa H, Inui N, Funai K Shinmura K, Niwa H, Suda T Abstract 3698: associations of the immune microenvironment with PD-L1 copy number alterations and PD-L1 expression in resected non-small cell lung cancer. AACR2017. 2017. p. 3698.
   Google Scholar
• Inoue Y, Yoshimura K, Kurabe N, Kahyo T, Kawase A, Tanahashi M, Ogawa H, Inui N, Funai K, Shinmura K, et al. Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer. Oncotarget. 2018;8:8738–8751. doi:10.18632/oncotarget.v8i5.
   Google Scholar
• Fong L, Forde PM, Powderly JD, Goldman JW, Nemunaitis JJ, Luke JJ, Hellmann MD, Kummar S, Doebele RC, Mahadevan D, et al. Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients. J Clin Oncol. 2017;35:3004. doi:10.1200/JCO.2017.35.15_suppl.3004.
   Web of Science ®Google Scholar
• Rizvi N, Shu C, Goldberg S, Papadimitrakopoulou V, Camidge DR, Patel S, Marrone K, Kim S, Kim D, Hsieh H, et al. P3.04-23 phase 1b/2 study to evaluate novel combinations with oleclumab (MEDI9447) in previously treated advanced EGFRm NSCLC. J Thorac Oncol. 2018;13:S930–1. doi:10.1016/j.jtho.2018.08.1730.
   Web of Science ®Google Scholar
• Suzuki Y, Suda T, Furuhashi K, Suzuki M, Fujie M, Hahimoto D, Nakamura Y, Inui N, Nakamura H, Chida K, et al. Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer. 2010;67(3):361–365. doi:10.1016/j.lungcan.2009.05.001.
   PubMed Web of Science ®Google Scholar
• Gangadhar TC, Schneider BJ, Bauer TM, Wasser JS, Spira AI, Patel SP, Balmanoukian AS, Bauml J, Schmidt EV, Zhao Y, et al. Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: preliminary phase I/II results of ECHO-202/KEYNOTE-037. J Clin Oncol. 2017;35(15_suppl):9014. doi:10.1200/JCO.2017.35.15_suppl.9014.
   Web of Science ®Google Scholar
• Pitt JM, Vétizou M, Daillère R, Roberti MP, Yamazaki T, Routy B, Lepage P, Boneca I, Chamaillard M, Kroemer G, et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity. 2016;44(6):1255–1269. doi:10.1016/j.immuni.2016.06.001.
   PubMed Web of Science ®Google Scholar
• Yoshimura K, Karayama M, Inoue Y, Kahyo T, Inui N, Maekawa M, Sugimura H, Suda T. Heterogeneous MET gene copy number and EGFR mutation elicit discordant responses to crizotinib between primary and metastatic lesions in erlotinib-resistant lung adenocarcinoma. Lung Cancer. 2018;124:317–319. doi:10.1016/j.lungcan.2018.03.016.
   PubMed Web of Science ®Google Scholar
• Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L. hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol. 2018;4:1543–1552. doi:10.1001/jamaoncol.2018.3676.
   Web of Science ®Google Scholar
• Yoshimura K, Inoue Y, Karayama M, Tsuchiya K, Mori K, Suzuki Y, Iwashita Y, Kahyo T, Kawase A, Tanahashi M, et al. Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: comparative assessment of primary and metastatic sites. Lung Cancer. 2019;134:202–209. doi:10.1016/j.lungcan.2019.06.002.
   PubMed Web of Science ®Google Scholar
• Barclay AN, Clark MJ, McCaughan GW. Neuronal/lymphoid membrane glycoprotein MRC OX-2 is a member of the immunoglobulin superfamily with a light-chain-like structure. Biochem Soc Symp. 1986;51:149–157.
   Google Scholar
• Barclay AN, Wright GJ, Brooke G, Brown MH. CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol. 2002;23:285–290. doi:10.1016/S1471-4906(02)02223-8.
   Web of Science ®Google Scholar
• Broderick C, Hoek RM, Forrester JV, Liversidge J, Sedgwick JD, Dick AD. Constitutive retinal CD200 expression regulates resident microglia and activation state of inflammatory cells during experimental autoimmune uveoretinitis. Am J Pathol. 2002;161:1669–1677. doi:10.1016/S0002-9440(10)64444-6.
   PubMed Web of Science ®Google Scholar
• Coles SJ, Wang ECY, Man S, Hills RK, Burnett AK, Tonks A, Darley RL. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia. 2011;25:792–799. doi:10.1038/leu.2011.1.
   PubMed Web of Science ®Google Scholar
• Wang L, Liu JQ, Talebian F, El-Omrani HY, Khattabi M, Yu L, Bai X-F. Tumor expression of CD200 inhibits IL-10 production by tumor-associated myeloid cells and prevents tumor immune evasion of CTL therapy. Eur J Immunol. 2010;40:2569–2579. doi:10.1002/eji.201040472.
   PubMed Web of Science ®Google Scholar
• Zhang S, Cherwinski H, Sedgwick JD, Phillips JH. Molecular mechanisms of CD200 inhibition of mast cell activation. J Immunol. 2004;173:6786–6793. doi:10.4049/jimmunol.173.11.6786.
   PubMed Web of Science ®Google Scholar
• Siva A, Xin H, Qin F, Oltean D, Bowdish KS, Kretz-Rommel A. Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. Cancer Immunol Immunother. 2008;57:987–996. doi:10.1007/s00262-007-0429-6.
   PubMed Web of Science ®Google Scholar
• Mahadevan D, Lanasa MC, Farber C, Pandey M, Whelden M, Faas SJ, Ulery T, Kukreja A, Li L, Bedrosian CL, et al. Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200. J Immunother Cancer. 2019;7:227. doi:10.1186/s40425-019-0710-1.
   PubMed Web of Science ®Google Scholar
• Ferrer I, Zugazagoitia J, Herbertz S, John W, Paz-Ares L, Schmid-Bindert G. KRAS-Mutant non-small cell lung cancer: from biology to therapy. Lung Cancer. 2018;124:53–64. doi:10.1016/j.lungcan.2018.07.013.
   Web of Science ®Google Scholar
• Papadimitrakopoulou V. Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. J Thorac Oncol. 2012;7:1315–1326. doi:10.1097/JTO.0b013e31825493eb.
   Web of Science ®Google Scholar
• Sun H, Xu J, Huang M, Huang Q, Sun R, Xiao W, Sun C. CD200R, a co-inhibitory receptor on immune cells, predicts the prognosis of human hepatocellular carcinoma. Immunol Lett. 2016;178:105–113. doi:10.1016/j.imlet.2016.08.009.
   PubMed Web of Science ®Google Scholar
• Bisgin A, Meng WJ, Adell G, Sun XF. Interaction of CD200 Overexpression on tumor cells with cd200r1 overexpression on stromal cells: an escape from the host immune response in rectal cancer patients. J Oncol. 2019;2019:1–7. doi:10.1155/2019/5689464.
   Web of Science ®Google Scholar
• Hoek RH, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM, Blom B, Homola ME, Streit WJ, Brown MH, Barclay AN. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science (80-). 2000;290:1768–1771. doi:10.1126/science.290.5497.1768.
   PubMed Web of Science ®Google Scholar
• Snelgrove RJ, Goulding J, Didierlaurent AM, Lyonga D, Vekaria S, Edwards L, Gwyer E, Sedgwick JD, Barclay AN, Hussell T, et al. A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat Immunol. 2008;9:1074–1083. doi:10.1038/ni.1637.
   PubMed Web of Science ®Google Scholar
• Mihrshahi R, Barclay AN, Brown MH. Essential roles for Dok2 and RasGAP in CD200 receptor-mediated regulation of human myeloid cells. J Immunol. 2009;183:4879–4886. doi:10.4049/jimmunol.0901531.
   PubMed Web of Science ®Google Scholar
• Zhang S, Phillips JH. Identification of tyrosine residues crucial for CD200R-mediated inhibition of mast cell activation. J Leukoc Biol. 2006;79:363–368. doi:10.1189/jlb.0705398.
   PubMed Web of Science ®Google Scholar
• Tonks A, Hills R, White P, Rosie B, Mills KI, Burnett AK, Darley RL. CD200 as a prognostic factor in acutemyeloid leukaemia. Leukemia. 2007;21:566-568. doi:10.1038/sj.leu.2404559.
   Web of Science ®Google Scholar
• Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E, Moine P, Bourin P, Moos M, Corre J, et al. CD200 is a new prognostic factor in multiple myeloma. Blood. 2006;108:4194–4197. doi:10.1182/blood-2006-06-029355.
   PubMed Web of Science ®Google Scholar
• Talebian F, Liu JQ, Liu Z, Khattabi M, He Y, Ganju R, Bai X-F. Melanoma cell expression of CD200 inhibits tumor formation and lung metastasis via inhibition of myeloid cell functions. PLoS One. 2012;7:e31442. doi:10.1371/journal.pone.0031442.
   Web of Science ®Google Scholar
• Erin N, Podnos A, Tanriover G, Duymuş CE, Khatri I, Khatri I, Gorczynski RM. Bidirectional effect of CD200 on breast cancer development and metastasis, with ultimate outcome determined by tumor aggressiveness and a cancer-induced inflammatory response. Oncogene. 2015;34:3860–3870. doi:10.1038/onc.2014.317.
   PubMed Web of Science ®Google Scholar
• Rygiel TP, Karnam G, Goverse G, Van Der Marel APJ, Greuter MJ, Van Schaarenburg RA, Visser WF, Brenkman AB, Molenaar R, Hoek RM, et al. CD200-CD200R signaling suppresses anti-tumor responses independently of CD200 expression on the tumor. Oncogene. 2012;31:2979–2988. doi:10.1038/onc.2011.477.
   PubMed Web of Science ®Google Scholar
• Rygiel TP, Meyaard L. CD200R signaling in tumor tolerance and inflammation: A tricky balance. Curr Opin Immunol. 2012;24:233–238. doi:10.1016/j.coi.2012.01.002.
   Web of Science ®Google Scholar
• Maeda Y, Nishikawa H, Sugiyama D, Ha D, Hamaguchi M, Saito T, Nishioka M, Wing JB, Adeegbe D, Katayama I, et al. Detection of self-reactive CD8 + T cells with an anergic phenotype in healthy individuals. Science. 2014;346:1536–1540. doi:10.1126/science.aaa1292.
   PubMed Web of Science ®Google Scholar
• Zhao S, Jiang T, Zhang L, Yang H, Liu X, Jia Y, Zhou C. Clinicopathological and prognostic significance of regulatory T cells in patients with non-small cell lung cancer: A systematic review with meta-analysis. Oncotarget. 2016;7:36065–36073. doi:10.18632/oncotarget.9130.
   PubMedGoogle Scholar
• Pollack SM, He Q, Yearley JH, Emerson R, Vignali M, Zhang Y, Redman MW, Baker KK, Cooper S, Donahue B, et al. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas. Cancer. 2017;123:3291–3304. doi:10.1002/cncr.v123.17.
   Google Scholar
• Akbar S, Jordan LB, Purdie CA, Thompson AM, McKenna SJ. Comparing computer-generated and pathologist-generated tumour segmentations for immunohistochemical scoring of breast tissue microarrays. Br J Cancer. 2015;113:1075–1080. doi:10.1038/bjc.2015.309.
   PubMed Web of Science ®Google Scholar
• Lu S, Stein JE, Rimm DL, Wang DW, Bell JM, Johnson DB, Sosman JA, Schalper KA, Anders RA, Wang H, et al. Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade. JAMA Oncol. 2019;5:1195–1204. doi:10.1001/jamaoncol.2019.1549.
   Web of Science ®Google Scholar
• Zhang SS, Huang ZW, Li LX, Fu JJ, Xiao B. Identification of CD200 + colorectal cancer stem cells and their gene expression profile. Oncol Rep. 2016;36:2252–2260. doi:10.3892/or.2016.5039.
   PubMed Web of Science ®Google Scholar
• Ren Y, Ye M, Chen S, Ding J. CD200 inhibits inflammatory response by promoting KATP channel opening in microglia cells in Parkinson’s disease. Med Sci Monit. 2016;22:1733–1741. doi:10.12659/MSM.898400.
   Web of Science ®Google Scholar
• Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, Nicholson AG, Groome P, Mitchell A, Bolejack V, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51. doi:10.1016/j.jtho.2015.09.009.
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, et al. The 2015 world health organization classification of lung tumors. J Thorac Oncol. 2015;10:1243–1260. doi:10.1097/JTO.0000000000000630.
   PubMed Web of Science ®Google Scholar
• Natsume H, Shinmura K, Tao H, Igarashi H, Suzuki M, Nagura K, Goto M, Yamada H, Maeda M, Konno H, Nakamura S. The CRKL gene encoding an adaptor protein is amplified, overexpressed, and a possible therapeutic target in gastric cancer. J Transl Med. 2012;10:97. doi: 10.1186/1479-5876-10-97.
   Web of Science ®Google Scholar
• Matsuura S, Kahyo T, Shinmura K, Iwaizumi M, Yamada H, Funai K, Kobayashi J, Tanahashi M, Niwa H, Ogawa H, et al. SGOL1 variant B induces abnormal mitosis and resistance to taxane in non-small cell lung cancers. Sci Rep. 2012;3:3012. doi:10.1038/srep03012.
   Web of Science ®Google Scholar
• Fukazawa Y, Lum R, Okoye AA, Park H, Matsuda K, Bae JY, Hagen SI, Shoemaker R, Deleage C, Lucero C, et al. B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat Med. 2015;21:132–139. doi:10.1038/nm.3781.
   PubMed Web of Science ®Google Scholar
• Ishibashi M, Neri S, Hashimoto H, Miyashita T, Yoshida T, Nakamura Y, Udagawa H, Kirita K, Matsumoto S, Umemura S, et al. CD200-positive cancer associated fibroblasts augment the sensitivity of epidermal growth factor receptor mutation-positive lung adenocarcinomas to EGFR Tyrosine kinase inhibitors. Sci Rep. 2017;7:46662. doi:10.1038/srep46662.
   Web of Science ®Google Scholar
• Cox FF, Carney D, Miller AM, Lynch MA. CD200 fusion protein decreases microglial activation in the hippocampus of aged rats. Brain Behav Immun. 2012;26:789–796. doi:10.1016/j.bbi.2011.10.004.
   PubMed Web of Science ®Google Scholar
• Ding Y, Yang H, Xiang W, He X, Liao W, Yi Z. CD200R1 agonist attenuates LPS-induced inflammatory response in human renal proximal tubular epithelial cells by regulating TLR4-MyD88-TAK1-mediated NF-κB and MAPK pathway. Biochem Biophys Res Commun. 2015;460:287–294. doi:10.1016/j.bbrc.2015.03.026.
   PubMed Web of Science ®Google Scholar
• Yoshimura K, Inoue Y, Mori K, Iwashita Y, Kahyo T, Kawase A, Tanahashi M, Ogawa H, Inui N, Funai K, Shinmura K. Distinct prognostic roles and heterogeneity of TTF1 copy number and TTF1 protein expression in non-small cell lung cancer. Genes Chromosom Cancer. 2017;56:570–581. doi:10.1002/gcc.22461.
   PubMed Web of Science ®Google Scholar
• Meng H, Chen G, Zhang X, Wang Z, Thomas DG, Giordano TJ, Beer DG, Wang MM. Stromal LRP1 in lung adenocarcinoma predicts clinical outcome. Clin Cancer Res. 2011;17(8):2426–2433. doi:10.1158/1078-0432.CCR-10-2385.
   PubMed Web of Science ®Google Scholar
• Mirastschijski U, Schnabel R, Claes J, Schneider W, Ågren MS, Haaksma C, Tomasek JJ. Matrix metalloproteinase inhibition delays wound healing and blocks the latent transforming growth factor-β1-promoted myofibroblast formation and function. Wound Repair Regen. 2010;18:223–234. doi:10.1111/wrr.2010.18.issue-2.
   PubMed Web of Science ®Google Scholar
• Kadota K, Nitadori JI, Ujiie H, Buitrago DH, Woo KM, Sima CS, Travis WD, Jones DR, Adusumilli PS. Prognostic impact of immune microenvironment in lung squamous cell carcinoma. J Thorac Oncol. 2015;10:1301–1310.
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 2007; 104(9):3360-3365. International Association for the Study of Lung Cancer. Available from
   Google Scholar
• Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–15550. doi:10.1073/pnas.0506580102.
   PubMed Web of Science ®Google Scholar
• Gyorffy B, Surowiak P, Budczies J, Lánczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 2013;8:e82241. doi:10.1371/journal.pone.0082241.
   Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1. doi:10.1126/scisignal.2004088.
   Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–404. doi:10.1158/2159-8290.CD-12-0095.
   PubMed Web of Science ®Google Scholar